Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis and Other Liver Diseases: Mechanisms, Clinical Evidence, and Future Directions
View Full Paper
Ask AI
Bookmark
Share
Discussion
Loading...
Member takes
Overview
Randomized trial evaluates PPAR agonists' impact on liver conditions, suggesting broader receptor targeting may enhance treatment efficacy.
Key Points
To explore the therapeutic potential of PPAR agonists in treating various liver diseases based on molecular mechanisms and clinical outcomes.
Review of clinical phase 3 trials evaluating elafibranor and seladelpar in primary biliary cholangitis (PBC).
Analysis of retrospective studies on bezafibrate use in Europe and Japan.
Synthesis of preclinical and clinical evidence regarding mono-, dual-, and pan-PPAR agonists across liver disease types.
Elafibranor and seladelpar showed significant biochemical response rates of 51% and 62%, respectively, compared to placebos of 4% and 20%.
Long-term benefits from elafibranor demonstrated sustained improvements in cholestatic biomarkers and stabilization of fibrosis markers over three years.
Bezafibrate exhibited survival benefits in large retrospective analyses and is utilized as second-line therapy.